GNPH - Genesis Pharmaceuticals Enterprises
Dtl. gestern noch ohne Umsatz (Handel erst seit heute möglich)
Info: Jahres-Finanzzahlen noch ausständig
Frage: hat jemand Infos/Regularien, inwiefern sich der R/S + Symbol-Umbennenung auf die Fristen zur Erstellung der Finanzzahlen auswirkt (Fristverlängerung etc.) ??
DANKE
Angehängte Grafik:
chart_gnph_080908.gif (verkleinert auf 80%)
chart_gnph_080908.gif (verkleinert auf 80%)
Schlecht ist das anscheinend kaum Interesse an dem Wert besteht in den USA.Dort kaum handel obwohl der Handel seit gestern voll laufen könnte.
Mit ein paar kleinen Verkäufen kann in den USA das Ding mächtig gedrückt werden bei dem geringen Volumen.
Bin mal gespannt aber einsteigen würde ich nicht zu diesen Kursen.
Posted by: _bbb_ Date: Tuesday, September 09, 2008 4:13:20 AM
In reply to: None Post # of 4777
Hey Boys, shouldn't the financials be out ? Or is there a delay because of the R/S or Symbolchange ?
**************************************************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32024607
Posted by: 996 Date: Tuesday, September 09, 2008 4:59:04 AM
In reply to: _bbb_ who wrote msg# 4776 Post # of 4778
I am confused, I have read about several things: 10 weeks after year-end, 90 days after year end. If you use 90 days after June 30th that makes end of September. Don't think that delay is granted because of R/S / symbolchange...
**************************************************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32024633
Posted by: _bbb_ Date: Tuesday, September 09, 2008 5:08:59 AM
In reply to: 996 who wrote msg# 4777 Post # of 4778
Thanks...hm...i got ask of ax on the german ariva board...looks like everybody is a bit confuzed....
...die Angaben sind ohne Gewähr --ax--
Genesis Pharmaceuticals Appoints New Board Member
LAIYANG, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ --
Genesis Pharmaceuticals Enterprises, Inc. (OTC:GNPH) (BULLETIN BOARD: GNPH) ('Genesis' or the 'Company'), a leading pharmaceutical company in the People's Republic of China, today announced that Mr. John Yang Wang was appointed to serve as a new member of the Company's Board of Directors effective September 8, 2008.
Mr. Wang founded and is the President of Marbella Capital Partners, serves as the CEO of Hambrecht Asia Acquisition Corp., and is on the Board of Directors of Hong Kong Stock Exchange listed Wuyi International Pharmaceuticals Company Limited. From 2000 to 2004, he was Executive Vice President of SBI E2-Capital (HK) Limited. From 1997 to 1999, he managed Accenture Consulting's (formerly known as Andersen Consulting) Greater China communication, media and high tech strategy practice. Prior to that, he was the lead telecom analyst covering Greater China and Southeast Asia for Pyramid Research, a Cambridge Massachusetts based emerging market telecom research firm. Mr. Wang holds a Bachelor of Arts in International Relations from Tufts University and an M.A.L.D. degree in international law and business from The Fletcher School of Law and Diplomacy. He has over 15 years of experience in investment banking and consulting and speaks fluent Mandarin and English.
The Board of Directors appointed Mr. Wang to be a member of the Company's Audit Committee and Compensation Committee.
'There is a great deal of demand throughout China for the high quality pharmaceutical products produced by Genesis. I believe that the Company has a great future,' said Mr. John Wang. 'Being on the Board of Directors of Genesis is an exciting opportunity for me to contribute to the growth of a rapidly expanding company in what I believe is an important industry.'
On September 9, 2008, the Board of Directors accepted the resignation of Mr. Robert Cain as a director of the Company. His resignation was not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices. Mr. Cain will continue to have a role with the Company as a consultant through the end of 2008.
'We are pleased to welcome John Wang to our Board of Directors. He brings a wide-ranging business background and management experience to the work of our Board,' said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. 'With John Wang on our Board of Directors, and a member of both our Audit Committee and Compensation Committee, Genesis is well positioned to meet the board requirements for companies that want to be listed on the Nasdaq.'
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO Tel: +1-954-727-8436 Email: Web: http://www.genesis-china.net/
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: Web: http://www.ccgir.com/
DATASOURCE: Genesis Pharmaceuticals Enterprises, Inc.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc. - Ms. Elsa Sung, CFO,
+1-954-727-8436, or ; CCG Investor Relations, Inc. - Mr.
Crocker Coulson, President, +1-646-213-1915, or
Web Site: http://www.genesis-china.net/
http://www.ccgir.com/
AS : reduced from 900,000,000 to 22,500,000
...die Aktien sind weniger geworden ! (nicht z.B. per Dilution etc. mehr geworden)
http://ih.advfn.com/...&cb=1221054793&article=28022313&symbol=NB^GNPH
On August 29, 2008, Genesis Pharmaceuticals Enterprises, Inc. (the “Company”) received confirmation from the Department of State of the State of Florida that the Articles of Amendment to the Amended and Restated Articles of Incorporation (“Amended Articles of Incorporation”) to effect a reverse stock split was duly filed and on September 3, 2008, the Company effected a reverse stock split pursuant to which each forty (40) currently outstanding shares of common stock, par value $0.001, were automatically converted into one (1) share of common stock, par value $0.001, and the total number of shares of our common stock outstanding was reduced from 412,986,078 shares to approximately 10,325,000 shares (the "Stock Split"). Pursuant to the Amended Articles of Incorporation, the maximum number of shares of common stock that the Company is authorized to issue was also reduced from 900,000,000 to 22,500,000.
...solange es sich nicht um Werbung für andere Aktien bzw. Beleidigung von Usern handelt, schreite ich nicht ein...
--ax--
Meine Meinung zur jetzigen Situation:
- bis zur Veröffentlichung der Jahres-Finanzzahlen wird sich an der monatelangen Seitwärt/Talfahrt-Bewegung nichts ändern...
Tatsache ist doch, dass nach diesem Split die mögliche Fallhöhe sehr groß ist. Ich bin der Meinung, es wäre solider, wenn die Aktiengesellschaften aus eigener Kraft in höhere Regionen des Kurses kämen...
Aber noch einmal: allen Investierten viel Glück!
Schreibt was ihr wollt...22,5 mill max O/S !
On August 29, 2008, Genesis Pharmaceuticals Enterprises, Inc. (the “Company”) received confirmation from the Department of State of the State of Florida that the Articles of Amendment to the Amended and Restated Articles of Incorporation (“Amended Articles of Incorporation”) to effect a reverse stock split was duly filed and on September 3, 2008, the Company effected a reverse stock split pursuant to which each forty (40) currently outstanding shares of common stock, par value $0.001, were automatically converted into one (1) share of common stock, par value $0.001, and the total number of shares of our common stock outstanding was reduced from 412,986,078 shares to approximately 10,325,000 shares (the "Stock Split"). Pursuant to the Amended Articles of Incorporation, the maximum number of shares of common stock that the Company is authorized to issue was also reduced from 900,000,000 to 22,500,000.
11.09.2008 20:47
Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
LAIYANG, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, (News) Inc. (BULLETIN BOARD: GNPH) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that the Company received purchase orders for a total value of approximately $12 million over the next 12 months from over 800 wholesale distributors at the 43rd Annual New Drugs Conference (the "Conference") sponsored by China Health Tech Forum 2008.
The 43rd Annual New Drugs Conference was held on September 3rd - 5th in Yantai International Expo Center, Shandong Province. The purpose of this industry Conference was to allow pharmaceutical companies in China with new and innovative products to meet and exchange ideas, and to allow pharmaceutical companies to introduce their products to distributors. Genesis distributed a large number of Company brochures at the Conference and received numerous inquiries from distributors.
The Company's newly developed Radix Isatidis Dispersible Tablets, an herbal-based traditional Chinese medicine, received the highest number of orders, over 60% of the total value of the purchase orders.
"We are pleased that the 43rd Annual New Drugs Conference was such a success for the Company. We believe that these new purchase orders from these distributors will increase our presence in the Chinese over the counter pharmaceuticals market," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We hope to expand our market share and get even greater brand recognition in China in the future by bringing new and innovative products to market."
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung, CFO Tel: +1-954-727-8435 Email: genesispharm@gmail.com
**************************************************
ausstehend im September: Bericht (Zahlen) Finanzjahr 2008 [Juli'07 bis Juni'08]
**************************************************
Wochenverlauf: 08.-12.09.2008
( -42% [von 13,5$ auf 7,86$] / Handelsvolumen 32,6K-Aktien )
Angehängte Grafik:
chart_gnph_wochenverlauf.gif (verkleinert auf 80%)
chart_gnph_wochenverlauf.gif (verkleinert auf 80%)
**************************************************
12.09 EDGAR (8-K) http://ih.advfn.com/...&cb=1221893212&article=28108678&symbol=NB^GNPH
**************************************************
Wochenverlauf: 15.-19.09.2008
( +11% [von 7,86$ auf 8,75$] / Handelsvolumen 6,7K-Aktien )
Angehängte Grafik:
chart_gnph_wochenverlauf.gif (verkleinert auf 80%)
chart_gnph_wochenverlauf.gif (verkleinert auf 80%)
**************************************************
16.09 EDGAR (Form 3) http://www.sec.gov/Archives/edgar/data/1091164/...5X02/v126547_ex.xml
Homepage (engl.) OFFLINE [update??] http://www.genesis-china.net/index.asp
Homepage (chin.) http://www.jiangbo.cn
**************************************************
Kurs Handelsplätze DTL.:http://www.ariva.de/quote/simple.m?secu=101235772
Wochenverlauf_USA: 22.-26.09.2008
( -0,57% [von 8,75$ auf 8,70$] / Handelsvolumen 10,5K-Aktien )
Angehängte Grafik:
chart_gnph_wochenverlauf.gif (verkleinert auf 80%)
chart_gnph_wochenverlauf.gif (verkleinert auf 80%)
29.09.2008 16:29
Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Fiscal Year 2008
LAIYANG, China, Sept. 29 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, (News) Inc. (BULLETIN BOARD: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern on Wednesday, October 1, 2008 to discuss financial results for its fourth quarter and fiscal year ended June 30, 2008.
Conference Call
Genesis Pharmaceuticals management will host a conference call at 9:00 a.m. Eastern on Wednesday, October 1, 2008 to discuss financial results for its fourth quarter and fiscal year 2008 ended June 30, 2008. The conference call will include Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 419-5570. International callers should call (617) 896-9871. The Conference Passcode is 375 022 62. If you are unable to participate in the call at that time, replay of the conference call will be available from Wednesday, October 1 at 11:00 a.m. Eastern until Wednesday, October 15. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Passcode is 31221366.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung CFO Phone: (561) 988-9880 E-mail: genesispharm@gmail.com http://www.genesis-china.net/ CCG Investor Relations, Inc. Mr. Crocker Coulson, President Phone: (646) 213-1915 E-mail: crocker.coulson@ccgir.com http://www.ccgir.com/